Chemical and analytical services are now widely available to the biomedical community. This accentuates the obligation of the Core to remain cost-effective to its users and to the NIH alike. While offering peptides of substantially higher purity, the Core's charges have remained comparable on a per-residue basis to the advertised commercial products. Especially important is the favorable cost differential for more complex peptides such as the long-acting """"""""M""""""""-PTH analogs and b-amino acid modifications needed under Project I. Savings are also being realized through our capability to perform syntheses on different scales, ranging from .002-.005 to 0.5 mmol, enabling costs to be matched with required quantity. The assets of the facility extend well beyond price considerations alone, however. The Core's staff has worked together for many years, and (starting with Drs. Potts and Keutmann) represents experience reaching back to the earliest days of protein sequencing and synthesis. Mr. Khatri brings broad expertise in contemporary synthetic and analytical methodology, having led us for over 20 years through the transition from t-BOC to Fmoc chemistry, the ongoing adoption of multiple-synthesis instrumentation, and innovative use of specialized protecting groups and coupling methodologies. Important among the """"""""value-added"""""""" benefits of an in-house Core facility is its ability to develop methodologies, not readily available on a commercial basis, in response to investigator needs--such as the long-acting pharmacokinetic analogs under Project I as noted above. This, and the very nature of peptide and protein chemistry, calls for extensive consultative interactions between investigators and Core staff. Updates on progress are available at any stage of the synthesis or analytical process--something not possible when ordering, catalog-style, from an outside vendor. Further, because of the Program Project's commitment of salaries and equipment to the Core, Program Project users receive a priority that assures faster service than is typically available commercially, especially for the longer and more complex peptides often required by Program investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
2P01DK011794-46
Application #
8659694
Study Section
Special Emphasis Panel (ZDK1-GRB-J (O1))
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
46
Fiscal Year
2014
Total Cost
$131,462
Indirect Cost
$55,909
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Bi, Ruiye; Fan, Yi; Lauter, Kelly et al. (2016) Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog. J Bone Miner Res 31:975-84
Stevenson, Hilary P; Lin, Guowu; Barnes, Christopher O et al. (2016) Transmission electron microscopy for the evaluation and optimization of crystal growth. Acta Crystallogr D Struct Biol 72:603-15
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2016) Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res :
Wein, Marc N; Liang, Yanke; Goransson, Olga et al. (2016) SIKs control osteocyte responses to parathyroid hormone. Nat Commun 7:13176
Eda, Homare; Santo, Loredana; Wein, Marc N et al. (2016) Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res 31:1225-34
Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon et al. (2016) Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. J Biol Chem 291:1631-42
Tenhola, Sirpa; Voutilainen, Raimo; Reyes, Monica et al. (2016) Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation. Eur J Endocrinol 175:211-8
Cheloha, Ross W; Watanabe, Tomoyuki; Dean, Thomas et al. (2016) Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist. ACS Chem Biol 11:2752-2762
Hattersley, Gary; Dean, Thomas; Corbin, Braden A et al. (2016) Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157:141-9

Showing the most recent 10 out of 195 publications